The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -23,503,329 |
| Depreciation and amortization | 983,706 |
| Amortization of operating lease right-of-use assets | 232,695 |
| Amortization of debt discount | 1,957,147 |
| (gain) / loss on disposal of fixed assets | 1,829 |
| Stock based compensation | 1,739,711 |
| Gain on change in derivative liability | 128,729 |
| Gain on change in fair value of warrant liability | 76,908 |
| Accounts receivable | 207,234 |
| Prepaid expenses | 95,020 |
| Other current assets | -150,736 |
| Accounts payable and accrued liabilities | 77,977 |
| Deferred revenue | -601,092 |
| Management and directors' fees payable | 50,853 |
| Operating lease liabilities | -262,018 |
| Net cash used in operating activities | -19,683,334 |
| Purchases of property and equipment | 89,558 |
| Purchase of license | 0 |
| Net cash used in investing activities | -89,558 |
| Net proceeds from issuance of common shares | 11,170,410 |
| Tax withholdings paid related to stock-based compensation | 210,034 |
| Proceeds from grants repayable | 111,043 |
| Proceeds from long-term debt | 1,980,178 |
| Net proceeds from issuance of convertible note and warrants | 5,802,779 |
| Payments on long-term debt | 877,550 |
| Payments on convertible loan note | 833,334 |
| Payments on grants repayable | 0 |
| Payments on financing leases | 50,634 |
| Net cash provided by financing activities | 17,092,858 |
| Effect of foreign exchange on cash and cash equivalents | 532,633 |
| Net change in cash and cash equivalents | -2,147,401 |
| Cash and cash equivalents - beginning of year | 3,264,429 |
| Cash and cash equivalents - end of year | 1,117,028 |
VOLITIONRX LTD (VNRX)
VOLITIONRX LTD (VNRX)